JAGUAR HEALTH, INC. Deferred Tax Assets, Operating Loss Carryforwards
JAGUAR HEALTH, INC. (JAGX) had Deferred Tax Assets, Operating Loss Carryforwards of $90.81 million as of 2025-12-31, per its 10-K filed 2026-04-07.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-04-07
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $90.81M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $77.75M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $51.85M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $24.77M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $90.81M 10-K · filed 2026-04-07 | |
| 2024-12-31 | $77.75M 10-K · filed 2026-04-07 | |
| 2023-12-31 | $51.85M 10-K · filed 2025-03-31 | |
| 2022-12-31 | $24.77M 10-K · filed 2024-04-01 | |
| 2021-12-31 | $21.15M 10-K · filed 2023-03-24 | |
| 2020-12-31 | $19.86M 10-K · filed 2022-03-11 | $19.86K 10-K · filed 2021-03-31 |
| 2019-12-31 | $15.97K 10-K · filed 2021-03-31 | $15.97M 10-K · filed 2020-04-03 |
| 2018-12-31 | $12.16M 10-K · filed 2020-04-03 | |
| 2017-12-31 | $5.83M 10-K · filed 2019-04-10 | |
| 2016-12-31 | $9.63M 10-K · filed 2018-04-09 | |
| 2015-12-31 | $7.46M 10-K · filed 2017-02-15 | |
| 2014-12-31 | $3.61M 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |